PFE · Earnings call · 2026Q3T · Full report

Lyme Vaccine Commercial Opportunity

PFIZER INC · 2026-11-03 · Importance 23 · Surprise 24

Management said the burden of Lyme disease is increasing globally and described the vaccine candidate partnered with Valneva as a commercial opportunity. Pfizer expects to draw on its European TicoVac franchise, sales force and pharmacy relationships in tick-borne disease-endemic areas to activate populations if the candidate is approved. Management said population awareness of Lyme disease is significantly higher than for tick-borne encephalitis in those markets. It also described rapidly increasing U.S. awareness, citing the disease’s severity and incidence.

Key facts

• Pfizer plans to commercialize its Lyme disease vaccine if it receives approval.
• Pfizer has the TicoVac franchise in Europe and uses a sales force and pharmacy commercial model to activate tick-borne populations in endemic areas.